Brief: Medivir Enters Into Exclusive Licensing Agreement With IGM Biosciences To Develop Birinapant

Medivir AB

11/01/2021 23:07

Jan 11 (Reuters) - Medivir  MVIRb.ST :
    * ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH IGM
BIOSCIENCES
FOR BIRINAPANT
    * IGM TO DEVELOP BIRINAPANT IN COMBINATION WITH IGM-8444 FOR
TREATMENT OF SOLID TUMORS
    * MEDIVIR WILL RECEIVE AN UPFRONT PAYMENT OF USD 1 MILLION
UPON
SIGNING AGREEMENT
    * ADDITIONAL USD 1.5 MILLION WHEN BIRINAPANT IS INCLUDED BY
IGM IN
CLINICAL PHASE I STUDIES
    * RECEIVE MILESTONE PAYMENTS UP TO A TOTAL OF APPROXIMATELY
USD
350 MILLION
    * IGM HOPES TO BEGIN CLINICAL TESTING OF BIRINAPANT IN
COMBINATION
WITH IGM-8444 FOR TREATMENT OF SOLID CANCERS LATER THIS YEAR

Source text for Eikon:  ID:nWkr96h8dg 
Further company coverage:  MVIRb.ST 

 ((Reuters.Briefs@thomsonreuters.com;))